生血宁和蔗糖铁对血液透析患者贫血、氧化应激及微炎症影响的比较 点击下载
| 论文标题： | 生血宁和蔗糖铁对血液透析患者贫血、氧化应激及微炎症影响的比较 |
| 英文标题： | |
| 中文摘要： | 目的：比较生血宁片和蔗糖铁注射液两种补铁方式治疗维持性血液透析（MHD）患者贫血的疗效及对氧化应激和微炎症状态的影响。方法：80例透析时间超过6个月的MHD患者按随机数字表法分为生血宁组和蔗糖铁组，各40例。两组患者透析频率均为每周3次，每次4 h，血流量为200～300 ml/min；均使用促红细胞生成素，每周1次，每次10 000 IU，皮下注射。在此基础上，生血宁组患者口服生血宁片，每次0.5 g，tid；蔗糖铁组患者在血液透析开始2 h后通过透析机静脉端输入100 mg蔗糖铁注射液，每周2次，完成总剂量1 000 mg后改为每周1次，使患者的血清铁蛋白（SF）维持在100～300 μg/L。检测两组患者治疗前及治疗12周后血红蛋白（Hb）、血细胞比容（Hct）、SF、转铁蛋白饱和度（TSAT）、高敏C反应蛋白（hs-CRP）、白细胞介素6（IL-6）、肿瘤坏死因子α（TNF-α）、过氧化物歧化酶（SOD）、谷胱甘肽过氧化物酶（GSH-Px）、丙二醛（MDA）水平的变化。结果：治疗12周后，两组患者的Hb、Hct、SF、TSAT较治疗前明显升高，差异有统计学意义（P＜0.01）；但组间比较差异无统计学意义（P＞0.05）。与治疗前比较，蔗糖铁组患者的MDA、IL-6、TNF-α、hs-CRP水平显著升高，SOD、GSH-Px水平显著降低，差异有统计学意义（P＜0.01）；但生血宁组患者的上述指标与治疗前比较无明显变化，因而两组间治疗后比较差异有统计学意义（P＜0.01）。两组患者均未见明显不良反应发生。结论：生血宁在改善MHD患者贫血、铁缺乏状态方面与蔗糖铁疗效接近，但不会加剧氧化应激及微炎症反应，是一种安全、有效的口服补铁药物。 |
| 英文摘要： | OBJECTIVE： To compare therapeutic efficacies of Shengxuening tablet and Iron sucrose injection for anemia in maintenance hemodialysis （MHD） patients， and their effects on oxidative stress and micro-inflammation state. METHODS： 80 patients who had received MHD over half year were assigned into shengxuening group and iron sucrose group with 40 cases in each group. Both groups received MHD 3 times a week， 4 h/time， blood flow of 200～300 ml/min； erythropoietin（EPO）was used at a dose of 10 000 IU/time hypodermically in each group. Shengxuening group was additionally given Shengxuening tablet orally， 0.5 g/time， tid. Iron sucrose group was given Iron sucrose injection 100 mg 2 h intravenously via dialyser after the beginning of hemodialysis， twice a week， received iron treatment every one week until complete the total dose of 1 000 mg， to maintain ferritin between 100～300 μg/L. The levels of Hb， Hct， SF， TSAT， hs-CRP， IL-6， TNF-α， MDA， SOD and GSH-Px were tested in 2 groups before and 12 weeks after the treatment. RESULTS： After 12 weeks of treatment， the levels of Hb， Hct， SF and TSAT in 2 groups were significantly increased， with statistical significance （P＜0.01）； but there was no statistical significance between 2 groups （P＞0.05）. Compared with before treatment， the levels of hs-CRP， IL-6， TNF-α and MDA increased significantly in iron sucrose group， while SOD and GSH-Px levels declined significantly， with statistical significance （P＜0.01）. Above indicators of shengxuening group had no significant change， compared with before treatment； there was statistical significance between 2 groups after treatment （P＜0.01）. No obvious ADR was found in 2 groups. CONCLUSIONS： Therapeutic efficacy of shengxuening is similar to that of iron sucrose in improving the anemia and iron deficiency status of MHD patients， but doesn’t aggravate oxidative stress and micro-inflammation state. It is an safe and effective oral iron supplement drugs. |
| 期刊： | 2016年第27卷第5期 |
| 作者： | 易晔，卢远航，冀倩倩 |
| 英文作者： | YI Ye，LU Yuanhang，JI Qianqian |
| 关键字： | 生血宁片；蔗糖铁注射液；血液透析；贫血；氧化应激；微炎症 |
| KEYWORDS： | Shengxuening tablet； Iron sucrose injection； Hemodialysis； Anemia； Oxidative stress； Micro-inflammation |
| 总下载数： | 81次 |
| 本日下载数： | 2次 |
| 本月下载数： | 81次 |
| 文件大小： | 619.60Kb |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！